A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company focused on unlocking the broad potential of ribonucleic acid (“RNA”) medicines (also known as oligonucleotides), or those targeting RNA, to transform human health. Our RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Our toolkit of RNA-targeting modalities includes RNA editing, splicing, silencing using RNA interference (“siRNA") and antisense silencing, providing us with unique capabilities for designing and sustainably delivering candidates that optimally address disease biology. Our diversified pipeline includes clinical programs in obesity, alpha-1 antitrypsin deficiency (“AATD”), Duchenne muscular dystrophy (“DMD”), and Huntington’s disease (“HD”), as well as several preclinical programs utilizing our versatile RNA medicines platform.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 108M | 113M | - | - |
| Net Income | -204M | -204M | -97M | -58M | -162M | -122M |
| EPS | $-1.21 | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 |
| Free Cash Flow | -188M | -188M | -152M | -21M | -129M | -90M |
| ROIC | -26.6% | -39.4% | -46.3% | -135.5% | -87.8% | -308.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.22 | 0.64 | 5.74 | -4.25 | 5.13 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -215M | -215M | -110M | -68M | -163M | -127M |
| Operating Margin | 0.0% | - | -101.9% | -60.0% | - | - |
| ROE | -39.4% | -56.2% | -46.3% | -145.1% | - | -212.1% |
| Shares Outstanding | 169M | 169M | 139M | 107M | 79M | 52M |
Wave Life Sciences Ltd. passes 0 of 9 quality checks, indicating weak fundamentals.
Wave Life Sciences Ltd. (WVE) has a 5-year average return on invested capital (ROIC) of -77.3%. This is below average and may indicate limited pricing power.
Wave Life Sciences Ltd. (WVE) has a market capitalization of $1.2B. It is classified as a small-cap stock.
Wave Life Sciences Ltd. (WVE) does not currently pay a regular dividend.
Wave Life Sciences Ltd. (WVE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Wave Life Sciences Ltd. (WVE) generated $-188 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Wave Life Sciences Ltd. (WVE) has a debt-to-equity ratio of 0.22. This indicates a conservatively financed balance sheet.
Wave Life Sciences Ltd. (WVE) reported earnings per share (EPS) of $-1.21 in its most recent fiscal year.
Wave Life Sciences Ltd. (WVE) has a return on equity (ROE) of -56.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 13 years of financial data for Wave Life Sciences Ltd. (WVE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Wave Life Sciences Ltd. (WVE) has a book value per share of $3.07, based on its most recent annual SEC filing.